These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? Converse PJ; Nuermberger EL; Almeida DV; Grosset JH Future Microbiol; 2011 Oct; 6(10):1185-98. PubMed ID: 22004037 [TBL] [Abstract][Full Text] [Related]
7. Buruli ulcer disease in Republic of the Congo. Marion E; Obvala D; Babonneau J; Kempf M; Asiedu KB; Marsollier L Emerg Infect Dis; 2014 Jun; 20(6):1070-2. PubMed ID: 24857328 [No Abstract] [Full Text] [Related]
8. Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update. O'Brien DP; Jenkin G; Buntine J; Steffen CM; McDonald A; Horne S; Friedman ND; Athan E; Hughes A; Callan PP; Johnson PD Med J Aust; 2014 Mar; 200(5):267-70. PubMed ID: 24641151 [TBL] [Abstract][Full Text] [Related]
9. Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. Schütte D; Umboock A; Pluschke G Br J Dermatol; 2009 Feb; 160(2):273-83. PubMed ID: 19016694 [TBL] [Abstract][Full Text] [Related]
10. [Streptomycin injections for the treatment of Mycobacterium ulcerans (Buruli ulcer) in a rural health zone in the Democratic Republic of the Congo]. Kibadi K Sante; 2007; 17(3):173-6. PubMed ID: 18180219 [TBL] [Abstract][Full Text] [Related]
11. [Mycobacterium ulcerans infection treated by Rifater, pyrazynamide, Myambutol, and surgery: a case report with a 6-year follow-up]. Kibadi K Med Mal Infect; 2008 Mar; 38(3):156-8. PubMed ID: 18079081 [TBL] [Abstract][Full Text] [Related]
12. Compliance with antimicrobial therapy for buruli ulcer. Klis S; Kingma R; Tuah W; Stienstra Y; van der Werf TS Antimicrob Agents Chemother; 2014 Oct; 58(10):6340. PubMed ID: 25225342 [No Abstract] [Full Text] [Related]
13. Reply to "compliance with antimicrobial therapy for buruli ulcer". Phillips RO; Sarfo FS; Abass MK; Frimpong M; Ampadu E; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M Antimicrob Agents Chemother; 2014 Oct; 58(10):6341. PubMed ID: 25225343 [No Abstract] [Full Text] [Related]
14. Severe multifocal form of buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms. Sopoh GE; Dossou AD; Brun LV; Barogui YT; Houézo JG; Affolabi D; Anagonou SY; Johnson RC; Kestens L; Portaels F Am J Trop Med Hyg; 2010 Aug; 83(2):307-13. PubMed ID: 20682873 [TBL] [Abstract][Full Text] [Related]
15. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473 [TBL] [Abstract][Full Text] [Related]
16. The surgical management of lesions of ulcerans infections due to Mycobacterium ulcerans, revisited. Radford AJ Trans R Soc Trop Med Hyg; 2009 Oct; 103(10):981-4. PubMed ID: 19457527 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546 [TBL] [Abstract][Full Text] [Related]